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the choice and consumption of brand name and generic OHAs
for each outpatient visit in the Deﬁned Daily Dose. RESULTS:
The regression results suggested a positive relationship between
the reimbursement price and probability of prescribing brand
name OHAs (odd ratio : 1.37, 95%CI : 1.36–1.37). The lower
reimbursement price likely results in the lower consumption of
both brand name (1.23; p < 0.01) and generic (0.93; p < 0.01)
OHAs. The price elasticity of brand name OHAs is greater than
that of generics OHAs. Large scale and private hospitals tend to
prescribe generic OHAs, and those with higher accreditation
level are inclined to prescribe brand name OHAs. CONCLU-
SION: The NHI price regulation generates the proﬁt margin
between reimbursement price and acquisition cost. Reducing the
reimbursement price may squeeze the proﬁt margin from brand
name drugs, likely resulting in decreasing the probability of pre-
scribing brand name drugs. The consumption of brand name
drugs tends to be more sensitive to price adjustment than that of
generic counterparts.
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OBJECTIVES: This study aims to investigate the relative risk
reduction (RRR) and number-needed-to-treat (NNT) estimates
related to lower limb amputation events among patients with
diabetic foot ulcer wounds using Negative Pressure Wound
Therapy (V.A.C.® Therapy) compared to a similar patient pop-
ulation receiving other wound care treatments. METHODS:
RRR and NNT estimates with NPWT in relation to an ampu-
tation event were evaluated using three distinct data sources.
Two retrospective administrative databases of diabetic ulcer
patients, including a commercial and a Medicare (CMS) popu-
lation, as well as RCT data for diabetic foot wound patients were
evaluated. RRR and NNT for lower limb amputation events
were calculated and compared between groups in each of the
three populations. RESULTS: The commercial data yielded over
3500 patients, the Medicare data included over 12,700 patients,
and the RCT included 162 patients. The RRR in amputation
occurrence with NPWT vs. the control group was 34% for the
commercial patient group and 35% for the Medicare patient
group. The RRR was found to be even greater in the RCT group
where NPWT was associated with over a 70% reduction in the
risk of an amputation event. The NNT to prevent one amputa-
tion event with NPWT therapy was 14 for the commercial
patient group, 18 for the Medicare patient group and 13 for the
RCT group. Target NNTs in the range of 12–35 have been
reported for preventing a subsequent adverse event. CONCLU-
SIONS: Using three different sources, this study is the ﬁrst to
evaluate the effectiveness of NPWT therapy by reporting calcu-
lated RRR and NNT related to lower limb amputations. The
NNT to prevent an amputation event with NPWT therapy was
consistent and low, ranging from 13 to 18. This data suggests
that NPWT therapy is an effective intervention in reducing risk
of amputation events in diabetic ulcer patients.
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OBJECTIVES: Achieving therapeutic goals in Type 2 diabetes
often becomes more difﬁcult as the disease progresses; many
patients eventually require treatment beyond oral hypoglycaemic
agents (OHA). The objective of this meta-analysis was to inves-
tigate which injectable therapies were either superior/inferior to
bedtime-administered insulin glargine, (glargine) for key clinical
outcomes. METHODS: A systematic review of all published
glargine clinical trials (prior to October 2005) was conducted.
Based on pre-deﬁned inclusion criteria, the review encompassed
all randomised controlled trials of at least eight-weeks duration
that compared combination therapies (injectable therapy and
OHA(s)), in insulin naïve patients. A random effects model was
employed to incorporate the variability in between-study condi-
tions. RESULTS: Seven trials met the speciﬁed criteria, with
glargine chosen as the reference regimen. Although biphasic
insulin aspart (BIA) and insulin lispro 75/25 were more efﬁca-
cious than glargine at reducing HbA1c (in unadjusted (adjusted)
analyses further reductions of −0.46 % (−0.41) and −0.39 % (−
0.40) respectively were observed), this increase in efﬁcacy was
also associated with relative increases in the risk of experiencing
hypoglycaemic events for both insulins and increased weight gain
for BIA. Compared to glargine, exenatide and NPH were equally
as efﬁcacious at reducing HbA1c, although patients taking exe-
natide also beneﬁted from weight reduction and a reduced risk
of experiencing a nocturnal hypoglycaemic event. With respect
to fasting blood glucose, exenatide, insulin lispro 75/25 and
NPH were less efﬁcacious than glargine. CONCLUSIONS: This
meta-analysis found a slight increase in efﬁcacy observed with
the two twice-daily insulin regimens compared to glargine;
however this result must be carefully balanced against the
observed increase in adverse events, especially for patients where
weight gain or hypoglycaemic events may be an issue. When
glargine was compared to exenatide, similar HbA1c reduction
was found but exenatide treated patients had fewer nocturnal
hypoglycaemic events and experienced weight loss.
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OBJECTIVE: To determine the time that patients with type 1
and type 2 diabetes remain on their existing therapy whilst
uncontrolled, before starting insulin or intensifying their insulin
regimen. METHODS: A retrospective cohort study was con-
ducted among subjects with type 1 and type 2 diabetes. A total
of 154 clinical practices with continuous data over a 10-year
period from 1st May 1995 until 30th April 2005 were included
in this analysis. The study identiﬁed 9979 individuals with type
1 diabetes (T1) and 62,533 individuals with type 2 diabetes (T2).
Four patient groups were analysed: T1 on premix regimens; T2
prescribed ≥2 orals; T2 on basal regimen and T2 on premix reg-
imens. The main study outcome was the median time to insulin
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initiation/intensiﬁcation in patients uncontrolled on their current
therapy. RESULTS: The median time to intensiﬁcation of insulin
regimen for T1 patients uncontrolled on premix regimens, was
4.0 years (95% CI 3.2 to 5.4). The median time to initiation of
insulin for T2 patients, prescribed two or more oral agents, with
evidence of poor glycaemic control was 7.0 years (95% CI 6.5
to 7.7). Finally, the median time to intensiﬁcation of the insulin
regimen was 4.2 years (95% CI 3.5 to 6.1) for T2 patients
uncontrolled on a basal regimen and >8 years for those uncon-
trolled on a premix regimen. CONCLUSION: In spite of poor
glycaemic control, insulin-naïve and insulin-treated patients fail
to initiate/intensify insulin therapy for many years. Earlier initi-
ation/intensiﬁcation of insulin therapy is likely to lead to better
control and a reduction in the complications associated with dia-
betes. Barriers to insulin use must be overcome if patients are to
achieve appropriate control.
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OBJECTIVES: As part of the submission to NICE, we evaluated
the cost-effectiveness of inhaled insulin (INH) in patients with
type 1 diabetes uncontrolled on a premix regimen (T1), and
patients with type 2 diabetes uncontrolled on oral anti-diabetic
drugs (T2). METHODS: Using the perspective of the National
Health Service (NHS), a validated Markov model (EAGLE) was
used to estimate the incremental costs and QALYs gained of: 1)
a basal bolus regimen involving INH versus an injected basal
bolus regimen in T1; and 2) a bolus of INH versus i) an injected
basal regimen and ii) an injected premix regimen in T2. The
model simulates the progression of diabetes in 1000 patients over
a time frame of 20 years. A large UK dataset was used to docu-
ment the patients’ clinical characteristics. NHS reference costs
were used as a source for medical costs. Utility/disutility data
were collected in published studies and clinical trial data were
used to document the efﬁcacy of therapies. An annual 3.5% dis-
count rate was used for both costs and outcomes. Probabilistic
sensitivity analysis was performed. RESULTS: In T1 the total
incremental costs (IC) were ≤202,746 and the total QALYs
gained (IE) were 24, leading to a mean incremental cost-effec-
tiveness ratio (ICER) of ≤8510/QALY. In T2, the mean lCER
versus basal was ≤24,285/QALY with IC of ≤497,749 and IE of
21. The mean ICER versus premix was ≤24,555/QALY with IC
of ≤503,185 and IE of 21. The probabilistic sensitivity analysis
showed that for a willingness to pay of ≤30,000 per QALY
gained, INH was cost-effective in 100% of the T1 simulations
and in 92 to 95% of T2 simulations. CONCLUSION: INH is a
cost-effective therapy for T1 and T2 patients uncontrolled on
their current therapy in the UK setting.
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OBJECTIVES: The objective of the study was to translate and
linguistically validate the Satisfaction with Oral Anti-Diabetic
Agents (SOADA) questionnaire for use in 11 countries. The
questionnaire was developed in the United States in 2005 in
order to assess satisfaction with oral anti-diabetic medication in
patients with type 2 diabetes. METHODS: The accepted stan-
dard methodology was used: 2 forward translations, reconcilia-
tion, 2 back translations, back translation review, developer
review, harmonisation meeting, linguistic validation interviews
with 5 or 6 patients with type 2 diabetes and 2 proof readings.
A universal approach was used for French and Spanish with the
aim of developing a single Spanish and a single French version.
RESULTS: While the majority of wording was easily agreed
upon, certain words and phrases were more troublesome. Issues
and solutions included: The ﬁrst French suggestion, “medica-
ment,” did not take into account the possibility of more than
one medication. The ﬁnal agreement was on “medicament(s).”
“Extremely [satisﬁed]” cannot be translated literally in Mexico
as it is too formal. “Muy satisfecho” was selected as the best
alternative for Mexico and Spain. “How quickly” was misun-
derstood in pilot testing in Korea so this was changed to a more
idiomatic “the ‘fastness’.” “Tolerabilidad,” the original Spanish
translation, was found to be problematic during cognitive
debrieﬁng interviews and a simpler alternative was found. The
universal approach produced a single ﬁnal version for French
and Canadian French and very similar ﬁnal translations for
Spanish (for Spain) and Mexican Spanish. CONCLUSIONS: The
SOADA has been translated and linguistically validated and is
now available for use in 11 countries. The universal approach
used for Spanish and French was successful. A number of cul-
tural and linguistic issues became apparent and were resolved.
The measure is now appropriate for use in multinational trials.
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OBJECTIVES: Two patient self-report questionnaires were
developed for use by physicians. They were intended to assess
why diabetic patients were reluctant to switch their treatment
from oral hypoglycaemic agents to insulin or to step up their
insulin dosage when already treated with insulin. This study pre-
sents scores and psychometric validation for both questionnaires.
METHODS: Patients treated with oral hypoglycaemic agents (n
= 1582) and patients already treated with insulin (n = 1296) com-
pleted the questionnaire at baseline, Month 3 and Month 6. Psy-
chometric properties were assessed: 1) structural analysis by
Principal Component Analysis (PCA) with varimax rotation; 2)
internal consistency reliability determination (Cronbach’s alpha);
and 3) concurrent validation (Spearman correlation coefﬁcients
with the Fear of Self-Injecting (FSI) score of the Diabetes Fear of
Injecting and Self-testing Questionnaire (D-FISQ). The ability of
scores to predict the switch to an insulin treatment and increased
numbers of injections at the end of baseline visit was established
by calculating the Area Under the ROC Curve (AUC). RESULTS:
PCA analysis conﬁrmed the ﬁnal questionnaire structure of 14
items grouped into 3 dimensions (Acceptance/Motivation (AM),
Insulin treatment: fear and constraints (FC), and Reluctance to
be injected (RI)). Internal consistency reliability (Cronbach’s
alpha ranging from 0.74 to 0.82) and concurrent validity (FIS
